peplin granted us patent for anti-cancer compounds

Peplin granted US patent for anti-cancer compounds
09:01, Wednesday, 6 April 2005

Sydney - Wednesday - April 6: (RWE Australian Business News) -

Peplin Ltd (ASX code: PEP) today announced the US Patent and Trademark
Office had granted the company a patent covering the use of its
macrocyclic anti-cancer compounds to stimulate the immune system.

Managing director and CEO Mr Michael Aldridge said the patent
provided Peplin valuable proprietary rights because these anti-cancer
compounds had a combined immune system stimulation and direct cytotoxic
effect.

These mechanisms of action had been studied extensively in
animal models.

"Our lead product, PEP005 Topical, directly kills most of the
cancer cells and then recruits and activates the local immune system to
clean-up the dead cancer cells and kill any remaining live cancer cells.

"We believe our drug has very powerful and unique mechanisms of
action," he said.

"The way our drug stimulates the body's immune system and more
particularly the local immune response following topical application is
an important component of how we are able to induce permanent resolution
of skin cancers," Mr Aldridge said.

Shares in Peplin fell 2c to 42c yesterday.

ENDS

http://www.sanford.com.au/sanford/Members/MarketInfo/News.asp?Source=RWE&ArticleID=248135